$NBIX News

Last published 1d ago

1d agoNBIXNeurocrine Biosciences to Present at the 2026 Jefferies Global Healthcare ConferencePR NewswireNeurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that its executives will participate at the 2026 Jefferies Global Healthcare...
1w agoNBIXNeurocrine Biosciences Reports 3rd Quarter 2026 Results - NEUROCRINE BIOSCIENCES INCEarnings Call TranscriptsHello and welcome everyone joining today's Neurogreen Biosciences third quarter 2026 earnings call. At this time all participants are in a listen-only mode. Later you will have the opportunity to ask questions during the
1w agoNBIXNEUROCRINE BIOSCIENCES INC - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
1w agoNBIXNeurocrine Biosciences Launches Interactive Educational Resources to Support Clinical Learning in Classic Congenital Adrenal HyperplasiaPR NewswireBootCAHmp® delivers evidence-based education to strengthen understanding of classic congenital adrenal hyperplasia through interactive learning and real-world patient casesDiscoverCAH™ provides immersive virtual
2w agoNBIXNeurocrine Biosciences Presents New Analysis Establishing Benchmark for Clinically Meaningful Change in Overall Health Reported by Patients with Tardive DyskinesiaPR NewswireNew analysis establishes a 6-point increase on the EQ Visual Analogue Scale as a threshold for clinically meaningful change in overall health ratings in patients with tardive dyskinesia treated with
2w agoNBIXApproval of Ingrezza, Nda #209241 (Labeling)FDA Approved DrugsApproval Date: 10/23/2026; Drug Name: Ingrezza, Nda #209241; Active Ingredients: VALBENAZINE TOSYLATE; Company: Neurocrine; Submission Status: Approval; Submission Classification: Labeling; Application Number: 209241
2w agoNBIXNeurocrine Biosciences Announces Publication in Orphanet Journal of Rare Diseases Advancing Understanding of Hyperphagia in Prader-Willi SyndromePR NewswireExpert perspectives highlight the interaction of hypothalamic dysfunction, biological, behavioral, and environmental factors in shaping the challenges of hyperphagia in Prader-Willi syndrome for patients and families
3w agoNTHI NBIX ACAD AVXL+1Brain Cancer Research: The Race for Better CNS Cancer Treatments Could Open a Multibillion-Dollar MarketGlobeNewswireNEW YORK, Oct. 21, 2026 (GLOBE NEWSWIRE) -- Brain cancer remains one of the hardest cancers to treat, and researchers are under pressure to find therapies that do more than slow the disease for a short time. For
3w agoNBIXNeurocrine Biosciences Initiates Phase 2 Clinical Study Evaluating NBI-'567 in Adults with Alzheimer's DiseasePR NewswireSAN DIEGO, Oct. 20, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced the initiation of its Phase 2 clinical study of investigational compound NBI-1117567 (NBI-'567) in adults with mild
3w agoNBIXNeurocrine Biosciences Presents Real-World Evidence Mapping the Lifelong, Evolving Impact of Classic Congenital Adrenal HyperplasiaPR NewswireDecades of real-world medical records highlight the diverse challenges of living with classic congenital adrenal hyperplasia and how needs evolve from childhood through adulthoodPatient records showed growth and
1mo agoNBIXNeurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2026 Financial ResultsPR NewswireConference Call and Webcast Scheduled for Monday, November 2SAN DIEGO, Oct. 12, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) announced today that it has scheduled its third quarter 2026 financial
1mo agoNBIXNeurocrine Biosciences to Present Research Advancing Understanding of Prader-Willi Syndrome and Real-World Experience with VYKAT® XR (diazoxide choline) at Foundation for Prader-Willi Research Symposium & Family ConferencePR NewswireNeurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced research advancing understanding of Prader-Willi syndrome and expanding clinical and...
1mo agoNBIXNeurocrine Biosciences Appoints Eiry W. Roberts, M.D., as Chief Medical OfficerPR NewswireNeurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that Eiry W. Roberts, M.D., who previously served as Neurocrine's Chief Medical Officer...
1mo agoNBIXNeurocrine Biosciences - 1773671 - NEUROCRINE BIOSCIENCES INCEarnings Call TranscriptsGood morning, everyone. I'm Sean Larmond, Head of US Mid-Cap Biotech Equity Research here at Morgan Stanley. Before we commence, to make you aware of some important disclosures, see those disclosions at the Morgan Stanle
2mo agoNBIXWells Fargo 21st Annual Healthcare Conference - NEUROCRINE BIOSCIENCES INCEarnings Call TranscriptsAwesome. Thank you very much for the post-lunch session, and we made it such that we have a very exciting company with us, to make sure you stay awake during the post lunch session here. So, we have New York in Managemen
2mo agoNBIXNeurocrine Biosciences to Present at Upcoming Investor Conferences in SeptemberPR NewswireNeurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that its executives will participate at the following investor conferences: Wells Fargo...
3mo agoNBIXNeurocrine Biosciences Announces Publication of KINECT-PRO™ Findings Demonstrating INGREZZA® (valbenazine) Capsules Improved Patient-Reported Quality of Life and Daily Functioning for People Living with Tardive DyskinesiaPR NewswireINGREZZA is the only vesicular monoamine transporter 2 inhibitor with clinical trial data demonstrating improvements in quality of life and functionality in people living with tardive dyskinesia across multiple
3mo agoNBIXNeurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBIP-'1968, a GLP-1/GIP/Glucagon Receptor Triple AgonistPR NewswireNeurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the initiation of a Phase 1 first-in-human clinical study evaluating the safety and...
3mo agoNBIXNeurocrine Biosciences Reports Second-Quarter 2026 Financial ResultsPR NewswireNeurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for the second quarter ended June 30, 2026. "Our second quarter...
3mo agoNBIXNeurocrine Biosciences Announces Key Leadership Hiring, PromotionsPR NewswireNeurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the appointment of three Senior Vice Presidents, further strengthening its leadership...
3mo agoNBIXNeurocrine Biosciences Appoints Samir Siddhanti Chief Business OfficerPR NewswireNeurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the appointment of Samir Siddhanti as Chief Business Officer and a member of the...
4mo agoNBIXNeurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2026 Financial ResultsPR NewswireNeurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it has scheduled its second quarter 2026 financial results conference call and...
4mo agoNBIXNeurocrine Biosciences Initiates Phase 2 Study of Crinecerfont in Pediatric Patients Under 4 Years Old with Classic Congenital Adrenal HyperplasiaPR NewswireNeurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the initiation of its Phase 2 clinical study to assess the safety and tolerability of...
4mo agoNBIXSoleno Therapeutics Presents New VYKAT® XR (diazoxide choline) Data at ENDO 2026 Demonstrating Meaningful and Durable Improvements in Hyperphagia and Behavioral Symptoms in Prader-Willi Syndrome Following Randomized Withdrawal PeriodPR NewswireSoleno Therapeutics, a Neurocrine Biosciences (Nasdaq: NBIX) company, today announced late-breaking data at ENDO 2026 showing that resuming treatment ...
4mo agoNBIXNeurocrine Biosciences Presents First Retrospective Case Series of CRENESSITY® (crinecerfont) in Patients with Classic Congenital Adrenal Hyperplasia Due to 11β‑Hydroxylase Deficiency at ENDO 2026PR NewswireNeurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced clinical findings from the first retrospective case series in pediatric and adult...
4mo agoNBIXNeurocrine Biosciences Presents New Two-Year CRENESSITY® (crinecerfont) Data Demonstrating Improved Growth Measures in Pediatric Patients with Classic Congenital Adrenal Hyperplasia at ENDO 2026PR NewswireNeurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced new two-year data from the Phase 3 CAHtalyst® Pediatric study showing positive growth...
4mo agoNBIXNeurocrine Biosciences Presents New Two-Year CRENESSITY® (crinecerfont) Data Demonstrating Improvements in Cardiometabolic Outcomes in Adults with Classic Congenital Adrenal Hyperplasia at ENDO 2026PR NewswireNeurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced new Phase 3 CAHtalyst® Adult study data demonstrating improved cardiometabolic outcomes...
5mo agoNBIXNeurocrine Biosciences Presents New Clinically Meaningful Response Data on Treatment of Tardive Dyskinesia, Reinforcing the Efficacy of INGREZZA® (valbenazine) Capsules Across a Broad Range of PatientsPR NewswireNeurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced new post-hoc data from the KINECT® 4 clinical trial demonstrating that adults with...
5mo agoNBIXNeurocrine Biosciences Presents New Data Highlighting Functional and Socio-emotional Improvements with INGREZZA® (valbenazine) Capsules in Individuals with Tardive Dyskinesia and Intellectual and Developmental DisabilitiesPR NewswireNeurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced new clinician-reported data in patients with intellectual and developmental disabilities...
5mo agoNBIXNeurocrine Biosciences to Present New Two‑Year CRENESSITY® (crinecerfont) Data on Key Clinical and Patient‑Reported Outcome Measures at ENDO 2026PR NewswireNeurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced it will present multiple new analyses of key clinical and patient-reported outcomes up to ...
5mo agoNBIXNeurocrine Biosciences to Present at Upcoming Investor Conferences in JunePR NewswireNeurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that its executives will participate at the following investor conferences: William Blair ...
5mo agoNBIXNeurocrine Biosciences Presents Real-World Data Highlighting Functional Impact of Mild Tardive Dyskinesia Severity and Improvement with INGREZZA® (valbenazine) CapsulesPR NewswireNeurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the presentation of new data from a clinician survey highlighting the functional impact...
5mo agoNBIXNeurocrine Biosciences Completes Acquisition of Soleno TherapeuticsPR NewswireNeurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the completion of its acquisition of Soleno Therapeutics, Inc., strengthening the...
6mo agoMREO NBIX4basebio Announces Appointment of Chief Financial Officer and Board ChangesGlobeNewswireRichard Bungay appointed as CFO, bringing a strong track record in fundraising, M&A and partnering for listed and private companies, including two major exits and over $400m raised Cambridge, UK, 14 May 2026 –
6mo agoNBIXNeurocrine Biosciences Announces Publication of Expert Recommendations for Glucocorticoid Dose Reduction after Initiating CRENESSITY® (crinecerfont) for the Treatment of Classic Congenital Adrenal HyperplasiaPR NewswireNeurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the publication of the first peer-reviewed expert recommendations to guide glucocorticoid ...
6mo agoNBIXNeurocrine Biosciences Reports First-Quarter 2026 Financial ResultsPR NewswireNeurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for the first quarter ended March 31, 2026. "Neurocrine's strong...
6mo agoNBIXNeurocrine Biosciences to Present at the Bank of America Health Care Conference 2026PR NewswireNeurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that its executives will participate at the Bank of America Health Care Conference 2026...
6mo agoNBIXNeurocrine Biosciences Announces New Survey Results Showing Significant Burden of Tardive Dyskinesia on EmploymentPR NewswireNeurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the release of findings from a new survey revealing the significant impact of tardive...
6mo agoNBIXNeurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBIP-'2118, a Corticotropin-Releasing Factor Type 2 Receptor AgonistPR NewswireNeurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the initiation of a Phase 1 first-in-human clinical study evaluating the safety and...
6mo agoNBIXNeurocrine Biosciences Presents New Two-Year CRENESSITY® (crinecerfont) Data Demonstrating Durable Hormone Control, Reduced Glucocorticoid Exposure and Meaningful Clinical Improvements in Pediatric Patients with Classic Congenital Adrenal HyperplasiaPR NewswireNeurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the presentation of new two-year data from the Phase 3 CAHtalyst® Pediatric study...
6mo agoNBIXNeurocrine Biosciences Announces Publication Establishing Clinically Meaningful Improvement Threshold for the Tardive Dyskinesia Impact ScalePR NewswireNeurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the publication of new peer-reviewed research in The Journal of Clinical Psychiatry...
6mo agoNBIXNeurocrine Biosciences Presents New Two-Year CRENESSITY® (crinecerfont) Data Showing Sustained Glucocorticoid Dose Reductions While Maintaining Androgen Control in Adults with Classic Congenital Adrenal HyperplasiaPR NewswireNeurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the first presentation of new two-year data from the Phase 3 CAHtalyst® Adult study...
7mo agoNBIXNeurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2026 Financial ResultsPR NewswireNeurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it has scheduled its first quarter 2026 financial results conference call and...
7mo agoNBIXNeurocrine Biosciences Presents First Real-World Head-to-Head Claims Analysis Demonstrating Greater Treatment Persistence with INGREZZA® (valbenazine) Capsules Compared to AUSTEDO XRPR NewswireNeurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the presentation of new real-world evidence demonstrating that adult patients with...
7mo agoNBIXApproval of Ingrezza Sprinkle, Nda #218390 (Labeling)FDA Approved DrugsApproval Date: 04/08/2026; Drug Name: Ingrezza Sprinkle, Nda #218390; Active Ingredients: VALBENAZINE TOSYLATE; Company: Neurocrine; Submission Status: Approval; Submission Classification: Labeling; Application Number: 218390
7mo agoNBIX SLNONeurocrine to Acquire Soleno Therapeutics, Expanding Its Endocrinology and Rare Disease PortfolioPR NewswireNeurocrine Biosciences, Inc. (Nasdaq: NBIX) and Soleno Therapeutics, Inc. (Nasdaq: SLNO) today announced that Neurocrine has entered into a...
7mo agoNBIXNeurocrine Biosciences Presents First Expert Consensus Recommendations for Tardive Dyskinesia in Long-Term Care SettingsPR NewswireNeurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the presentation of the first expert consensus recommendations focused on screening,...
7mo agoNBIXNeurocrine Biosciences Appoints Andrew Ratz, Ph.D., as Chief Technical Operations OfficerPR NewswireNeurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the promotion of Andrew Ratz, Ph.D., to the executive management team as the Chief...
8mo agoNBIXNeurocrine Biosciences to Present at the Stifel 2026 Virtual CNS ForumPR NewswireNeurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that members of the management team will participate at the Stifel 2026 Virtual CNS Forum ...
8mo agoEFX NBIXBetterInvesting™ Magazine Update on Equifax Inc. (NYSE: EFX) and Neurocrine Bio In. (NASDAQ: NBIX)PR NewswireEquifax Inc.'s recent report has investors wondering if the company's stock is fairly valued. Or is it in the buy range? As such, the Editorial...